In the UK, wide‑ranging reforms coming into force on 28 April 2026 are designed to streamline approvals, embed a more ...
FDA approval introduces first-in-class, once-daily oral TYK2 inhibition for active psoriatic arthritis, expanding deucravacitinib beyond its 2022 plaque psoriasis indication. POETYK PsA-1 and PsA-2 ...
A 2026 informational consumer research report examining FocusMax cognitive support marketing claims, ingredient-level research context, proprietary blend transparency, pricing disclosures, and verific ...
An informational industry analysis examining ingredient-level research, marketing positioning trends, regulatory context, and ...
Moby summary of Amylyx Pharmaceuticals, Inc.'s Q4 2025 earnings call ...
The bispecific ADC izalontamab brengitecan improved survival for patients with metastatic triple-negative breast cancer in a ...
The MHRA has licensed brensocatib as the first disease-specific therapy for non-cystic fibrosis bronchiectasis in patients with recurrent exacerbations.
Healthdirect, Australia's national virtual health service provider, has recently introduced a patient consultation summary ...
Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026Breast cancer triplet data ...
Commercial readiness activities are scaling up in anticipation of a Q4 2026 launch, including the successful validation of a U.S.-based manufacturing process. The company maintains a strong liquidity ...
A guide to Medicare coverage for breast cancer diagnosis and treatment, including cost differences between Original Medicare ...
Huntington Beach, California - February 24, 2026 - PRESSADVANTAGE - A newly released educational resource provides a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results